New treatment option for Alzheimer patients

The two IREM professors Roger Nitsch and Christoph Hock with their UZH spin-off company Neurimmune AG reached a major milestone in the development of a treatment for Alzheimer patients: The antibody Aducanumab which binds and removes brain amyloid in patients with Alzheimer’s disease was recently approved by the American medicine agency FDA for the treatment of Alzheimer's disease.

Roger Nitsch is also part of the BEI program's Steering Board and his exciting talks frequently inspire life scientists to build-up their own start-up companies.

Christina Sina